Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Internet GHB Bust Could Lead To Future Web Shakedowns – DEA

This article was originally published in The Tan Sheet

Executive Summary

Leads and information obtained from a recent "takedown" of online gamma hydroxybutyrate (GHB) traffickers could result in future investigation and arrests, the Drug Enforcement Administration stated

You may also be interested in...



GHB Analog-Containing Product Demand High, NEJM Researchers Report

Extensive industrial use of the GHB analog 1,4-butanediol (BD), in conjunction with the flexibility and anonymity of Internet marketing, "ensures a continued supply that is almost impossible to regulate," researchers say in the Jan. 11 New England Journal of Medicine.

FDA Criminal Investigations Of Unapproved Drug Internet Sales Ongoing

FDA's Office of Criminal Investigations has 134 Internet-related investigations under way, 80 of which involve "various types of health fraud or other unapproved drug products" such as GHB. The other 54 cases involve Web sites selling prescription drugs.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel